Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

周二，RBC Capital Markets调整了Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)的目标价，从之前的400美元略微上调至401美元。该公司维持对这家生物科技公司股票的"行业表现"评级，目前股价为404.07美元。根据 InvestingPro 分析，该股票的交易价格略高于其公允价值，分析师目标价范围在325美元至602美元之间。

12月19日，专注于罕见病治疗的药品开发公司Vertex Pharmaceuticals（$福泰制药(VRTX)$）的股价大跌13%，原因是该公司公布的一项后期临床试验结果表现不佳。尽管如此，这一短期挫折并不足以改变这只制药股票的长期投资逻辑。对于愿意长期持有的投资者来说，这反而是一次逢低买入的好机会。 以下是具体原因分析。 Vertex因治疗罕见肺病囊性纤维化（CF）的药物而闻名。相关治疗方案不 ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...